Journal of Opioid Management,
Journal Year:
2023,
Volume and Issue:
19(7), P. 135 - 140
Published: Oct. 18, 2023
Buprenorphine
(BUP)
is
increasingly
recognized
and
utilized
as
a
valuable
medication
for
the
treatment
of
opioid
use
disorder.
This
article
focuses
on
problem
regulatory
restrictions
access
to
buprenorphine
products
without
naloxone
(mono-product),
involving
patients
in
one
geographic
area,
but
which
may
represent
more
general
United
States.In
response
an
audit
by
Tennessee
Board
Pharmacy,
pharmacy
northeast
designed
questionnaire
survey
patient
motivation
traveling
long
distances
fill
their
prescriptions
BUP,
rather
than
buprenorphine/naloxone
(BNx,
combo-product),
document
satisfaction
with
mono-product.Questionnaires
were
submitted
194
patients,
living
Tennessee,
southwest
Virginia,
southeast
Kentucky.
Significant,
intolerable,
side
effects
reported
all
prescribed
BNx,
because
legislative
respective
states,
they
unable
obtain
BUP
closer
home.
Consequently,
required
drive
significant
from
homes
prescriptions,
median
distance
52
miles,
some
cases
far
216
miles
round
trip.
Intolerable
reactions
included
severe
headaches,
nausea
vomiting,
allergies,
dysphoria.
All
tolerated
clinically
well
maintained
mono-product.Severe,
intolerable
reactions/side
component
BNx
are
not
uncommon,
mono-product
prohibit
providers
pharmacies
states
prescribing
dispensing
BUP.
The
participants
this
qualitative
study
found
it
necessary
travel
medication,
thereby
potentially
limiting
life-saving
therapy.
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 8, 2024
Abstract
Background
The
overdose
epidemic
is
presently
driven
by
polydrug
use,
sparking
renewed
interest
in
why
people
initiate
use
of
certain
drugs
or
drug
combinations.
Current
research
privileges
the
physiological
ends
consumption,
often
ignoring
social
and
environmental
context
use.
Framed
cognitive
theory,
purpose
this
study
was
to
characterize
factors
precipitating
substance
initiation,
transition,
combination
beyond
immediate
effects
substance(s).
Methods
We
conducted
30
semi-structured
interviews
with
who
across
North
Carolina,
exploring
history
risk
protective
Participants
also
completed
a
visual
timeline
activity.
used
staged
analytic
approach,
beginning
deductive
Structural
Coding
ending
inductive
Reflexive
Thematic
Analysis
at
both
transcript
excerpt
levels.
Results
conceptualized
transitions
as
pragmatic
processes
within
environments
constraints
opportunities.
Socially,
choices
were
desire
for
interpersonal
bonding,
pressure
assimilate
practices
one’s
circles,
ubiquity
milieu.
Transitions
shaped
–
which
substances
are
locally
available,
logistical
convenience
competing
substances,
material
costs
Conclusions
Beyond
new
enhanced
effects,
serve
practical
functions,
like
facilitating
emotional
closeness
ensuring
stable
supply.
Interventions
reduce
risks
should
account
these
contextual
instance,
educating
on
strategies
avoid
normative
pressures
promoting
safe,
affordable,
accessible
American Journal on Addictions,
Journal Year:
2023,
Volume and Issue:
32(6), P. 615 - 618
Published: Aug. 6, 2023
Abstract
Background
and
Objectives
We
explored
potential
challenges
to
accessing
office‐based
opioid
treatment
(OBOT)
with
buprenorphine
during
the
COVID‐19
pandemic.
Methods
Using
Facebook
advertisements,
we
recruited
a
sample
of
N
=
72
participants
conducted
four
repeated‐measures
analysis
variance
comparing
ratings
participants'
abilities
access
aspects
OBOT
treatment.
Results
Participants
reported
increased
difficulty
filling
prescriptions
pandemic
than
before,
p
.011,
partial
η
2
0.092,
this
was
correlated
past
month
use,
r
.236,
.042.
Discussion,
Conclusions,
Scientific
Significance
This
is
first
investigation
report
unfilled
an
association
use.
Unfilled
may
contribute
relapse
partially
explain
overdose
deaths
COVID‐19.
Journal of Opioid Management,
Journal Year:
2023,
Volume and Issue:
19(7), P. 135 - 140
Published: Oct. 18, 2023
Buprenorphine
(BUP)
is
increasingly
recognized
and
utilized
as
a
valuable
medication
for
the
treatment
of
opioid
use
disorder.
This
article
focuses
on
problem
regulatory
restrictions
access
to
buprenorphine
products
without
naloxone
(mono-product),
involving
patients
in
one
geographic
area,
but
which
may
represent
more
general
United
States.In
response
an
audit
by
Tennessee
Board
Pharmacy,
pharmacy
northeast
designed
questionnaire
survey
patient
motivation
traveling
long
distances
fill
their
prescriptions
BUP,
rather
than
buprenorphine/naloxone
(BNx,
combo-product),
document
satisfaction
with
mono-product.Questionnaires
were
submitted
194
patients,
living
Tennessee,
southwest
Virginia,
southeast
Kentucky.
Significant,
intolerable,
side
effects
reported
all
prescribed
BNx,
because
legislative
respective
states,
they
unable
obtain
BUP
closer
home.
Consequently,
required
drive
significant
from
homes
prescriptions,
median
distance
52
miles,
some
cases
far
216
miles
round
trip.
Intolerable
reactions
included
severe
headaches,
nausea
vomiting,
allergies,
dysphoria.
All
tolerated
clinically
well
maintained
mono-product.Severe,
intolerable
reactions/side
component
BNx
are
not
uncommon,
mono-product
prohibit
providers
pharmacies
states
prescribing
dispensing
BUP.
The
participants
this
qualitative
study
found
it
necessary
travel
medication,
thereby
potentially
limiting
life-saving
therapy.
